Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Doxorubicin with Olaratumab in Advanced Soft Tissue Sarcoma
NCT02326025Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2015
- Primary completion
- May 2015
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaratumab in soft tissue sarcoma (STS) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Area Under The Concentration Curve Zero to Infinity (AUC[0-∞]) Doxorubicin and Maximum Concentration (Cmax) Doxorubicin. Started Jan 2015; status: completed.
02
Drugs
olaratumab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT02326025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02326025.